In a report issued on May 11, Kumaraguru Raja from Brookline Capital Markets reiterated a Buy rating on Atreca (BCEL – Research Report), with a price target of $17.00. The company's shares closed last Friday at $1.67, close to its 52-week low of $1.56. According to TipRanks.com, Raja is a 1-star analyst with an average return of -1.6% and a 29.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Oncternal Therapeutics, and Caladrius Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $18.00 average price target, a 946.5% upside from current levels.
https://www.tipranks.com/news/blurbs/brookline-capital-markets-thinks-atrecas-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Atreca Charts.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Atreca Charts.